Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
2.140 USD   -5.31%
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Development Projects
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Invivyd, Inc. has Changed its Ticker to IVVD from ADGI

09/13/2022 | 12:00am EST

Effective September 13, 2022, Invivyd, Inc. changed its Nasdaq Global Market stock ticker symbol to IVVD from ADGI.


ę S&P Capital IQ 2022
All news about INVIVYD, INC.
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Develo..
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
GL
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
CI
11/10INVIVYD, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Transcript : Invivyd, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/10Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GL
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -236 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -0,99x
Yield 2022 -
Capitalization 233 M 233 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 102
Free-Float 72,5%
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 2,14 $
Average target price 3,83 $
Spread / Average Target 79,1%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Frederick W. Driscoll Chief Financial & Accounting Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.-70.52%233
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930